Markets

Immunomedics Provides Blockbuster Breast Cancer Survival Data

Over the weekend, Immunomedics (NASDAQ: IMMU) presented previously undisclosed clinical trial results for Trodelvy, a recently approved cancer drug. Gilead Sciences (NASDAQ: GILD) turned a lot of heads when it offered a 108% premium in its buyout bid for Immunomedics earlier this month, but it looks like that pricey gamble is going to work out just fine.

Trodelvy earned an accelerated approval from the FDA in April because it shrank tumors for a high percentage of patients with triple-negative breast cancer (TNBC), a particularly aggressive form of the disease that doesn't respond well to any of the targeted therapies oncologists previously had in their arsenal.

Laboratory technician with pippette.

Image source: Getty Images.

In order to earn full approval from the FDA, Trodelvy needed to prove it actually improves patients' chances of long-term survival, and with this data release, it knocked that challenge out of the park. Treatment with Trodelvy reduced TNBC patients' risk of death by 52% compared to patients given a physician's choice of standard treatment options.

Trodelvy is a first-in-class antibody that delivers a miniature dose of chemotherapy to cancer cells that exhibit a protein called Trop-2 on their surface, and it probably has a future beyond TNBC. Over the weekend, Immunomedics also presented results from a phase 2 study of it as a treatment for advanced-stage bladder cancer patients who have already relapsed multiple times. Trodelvy shrank tumors for an impressive 31 patients from a group of 113, six of whom achieved complete remission.

Before the end of 2020, Immunomedics expects to submit an application to the FDA that could expand Trodelvy's addressable patient population to include people with late-stage bladder cancer.

10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 1, 2020

 

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Immunomedics. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More